Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board  >  Regen BioPharma Inc    

REGEN BIOPHARMA INC
My previous session
Most popular
  Report  
End-of-day quote. End-of-day quote  - 06/22
0.0424 USD   +6.00%
SummaryChartsNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/12/2018 | 06:38pm CET

Item 5.03 Amendments to Articles of Incorporation

On October 11, 2018Regen Biopharma, Inc. amended its Certificate of Incorporation increasing its authorized common shares from 500,000,000 with a par value of 0.0001 to 800,000,000 with a par value of 0.0001

2

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGEN BIOPHARMA INC
12/03ENTEST GROUP, INC. : Changes in Control or Registrant, Change in Directors or Pr..
AQ
11/28ENTEST : Management's Discussion and Analysis of Financial Condition and Results..
AQ
11/20REGEN BIOPHARMA INC : Entry into a Material Definitive Agreement, Termination of..
AQ
11/20ENTEST GROUP, INC. : Entry into a Material Definitive Agreement, Termination of ..
AQ
10/12REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal..
AQ
10/04REGEN BIOPHARMA INC : Regulation FD Disclosure, Other Events (form 8-K)
AQ
10/04REGEN BIOPHARMA INC : Unregistered Sale of Equity Securities (form 8-K)
AQ
09/18Palatin Technologies, Inc. - Immunotherapy Market Value Grows as the Treatmen..
AQ
08/31REGEN BIOPHARMA : Reports Success of its NR2F6 Small Molecule Screening Program ..
AQ
08/06REGEN BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
More news
Chart REGEN BIOPHARMA INC
Duration : Period :
Regen BioPharma Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
David Raymond Koos Chairman, CEO, Secretary & Treasurer
Harry M. Lander President & Chief Scientific Officer
Todd S. Caven Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
REGEN BIOPHARMA INC-48.32%0
GILEAD SCIENCES-8.47%84 823
VERTEX PHARMACEUTICALS15.72%43 460
REGENERON PHARMACEUTICALS1.39%40 527
GENMAB3.84%9 952
SAREPTA THERAPEUTICS INC114.81%7 987